Silver Sponsor

hVIVO is the world leader in testing infectious & respiratory disease products using Human challenge studies addressing the growing infectious disease market.

hVIVO’s mission: Delivering today’s healthcare by empowering tomorrow’s innovation.

hVIVO’s vision: To transform global healthcare by revolutionising the drug development process through scientific ingenuity.

It is a trusted partner and industry-leading clinical development services business pioneering human disease models based upon viral challenge. These phase II trials are run from our 19-bedroom Whitechapel clinic, Europe's only 24-bedroom quarantine clinic with an onsite virology laboratory in London and an additional 12-bedroom facility in Plumbers Row, London.

hVIVO use human challenge studies to establish early proof-of-concept, hVIVO’s clinical trial platform can accelerate drug and vaccine development in respiratory and infectious disease. hVIVO supports product development for customers developing antivirals, vaccines and respiratory therapeutics. The company has a leading portfolio of more than 11 viral challenge study models, including: Flu (A & B), RSV, HRV, COVID-19 & Malaria model, no other company in the world has such a portfolio.

Over the years we have completed more than 70 studies and inoculated over 4,000 healthy volunteers.

hVIVO has played an active role in the fight against COVID-19; in March 2020 hVIVO initiated the development of a number of Coronavirus challenge study model. On the 20th of October 2020, Open Orphan announced the signing of a contract between their subsidiary, hVIVO, with the UK Government to develop a COVID-19 (SARS-CoV-2) human challenge study model. The model development involves the manufacture of the challenge virus and the first-in-human characterisation study for this virus. In addition, the Government has secured the first three slots to test vaccines using hVIVO's COVID-19 challenge study.